RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks.

RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Abstract Text:

H-C Diener, ,

A global, double-blind, randomized, placebo-controlled, dose-finding, parallel-group trial was conducted to compare three oral doses of RPR100893 (1, 5, 20 mg), a substance-P antagonist, and placebo in 139 patients with migraine attacks with moderate or severe headache intensity. Headache intensity and improvement of headache after 2 h were not different in the four treatment groups. Therefore, it is concluded that this oral substance-P antagonist in the doses used here is not effective.

RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Publishing Authors By Initials

HC Diener, ,

For similar peptides: intercellular signaling peptides and proteins: kinins: tachykinins: substance p research abstracts see: peptides: intercellular signaling peptides and proteins: kinins: tachykinins: substance p research

PUBMED ID PMID:

MEDLINE DATE:

RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cephalalgia : an international journal of headache

VOLUME: 23

Page Numbers: 183-5

Journal Abbreviation: Cephalalgia

ISSN: 0333-1024

DAY: 11

MONTH: Apr

YEAR: 2003

RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8200710

RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Keywords Mesh Terms:

KEYWORDS: Substance P

MESH TERMS: physiology

Chemical & Substance for Abstract: RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Information

Substance Name: Substance P

Registry Number: 33507-63-0

Grant and Affiliation Information for RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks.

AFFILIATION: Department of Neurology, University of Essen, Essen, Germany. h.diener@uni-essen.de

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cephalalgia

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks Related Publications

• A personal view of the classification and definition of drug dependence headache.
• Antiplatelet agents and randomized trials.
• Ca( 2+ )-induced cl (-) efflux at rat distal colonic epithelium.
• Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
• Cortical activation in hemianopia after stroke.
• Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine.
• Effect of carbon dioxide, temperature, and relative humidity on production of aflatoxin in peanuts.
• Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms.
• How can PET scans help us understand headache mechanisms?
• Low-dose aspirin for migraine prophylaxis in women.
• Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo.
• Placebo in headache trials.
• RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks.
• Saccade induced cortical activation in patients with post-stroke visual field defects.
• Se02 the validity of an integrated clinical simulator for learning laparoscopic appendicectomy.
• Stimulation of voltage-dependent Ca2+ channels by NO at rat myenteric neurons.
• Sumatriptan in the treatment of cluster headache.
• Sumatriptan: vasoactive effect on human dural vessels, demonstrated by subselective angiography.
• Systemic Risk Score Evaluation in Ischemic Stroke Patients (SCALA) : A prospective cross sectional study in 85 German stroke units.
• Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome?
• Use of almotriptan in triptan-experienced and triptan-naïve patients.
• [Abortion after the 12th completed pregnancy week. Report of experience of a specialist commission]
• [Development of a screening tool for migraine prophylaxis]
• [Incidence of hidden iron deficiency in women, especially in pregnancy and puerperium.]
• [Monitoring stroke units: management, outcome, efficiency]
• [On the applicability of vaginal cytology in the determination of delivery term and in the recognition of prolonged pregnancy]
• [Pathogenesis of anemia in myomas.]
• [Results in the management of pregnancies involving risk factors]
• [Serologic toxoplasmosis control in pregnancy using enzyme immunoassay (EIA). 1st experiences]
• [The change of cervical state during pregnancy (author's transl)]